GLENMARK PHARMA Fact Sheet, GLENMARK PHARMA Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA Fact Sheet   (GLPH)


Update: Richa is Very Bullish on this Little-known Smallcap Stock


Here is the latest financial fact sheet of GLENMARK PHARMA. For more details, see the GLENMARK PHARMA quarterly results and GLENMARK PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

GLENMARK PHARMA Price History

Price Rs 387.5
Mkt Cap Rs m 109,326
Vol '000 24.6
P/E X 11.0
P/CF X 7.7
EPS (TTM) Rs 35.2
1 Day % 0.3
No. of shares m 282.17
1 Week % 10.1
1 Month % -2.7
1 Year % -41.9
52 week H/L Rs 690.6/348.9
As on Jun 28, 2022 (Close)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

GLENMARK PHARMA Financials

No. of Mths
Year Ending
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
12
Mar-20
*
12
Mar-21
*
5-Yr Chart
Click to enlarge
GLENMARK PHARMA EQUITY SHARE DATA
High Rs993930712660573 
Low Rs729517484168195 
Sales per share (Unadj.) Rs318.0320.6349.6377.1387.8 
Earnings per share (Unadj.) Rs39.328.532.827.534.4 
Diluted earnings per shareRs39.328.532.827.534.4 
Cash flow per share (Unadj.) Rs48.739.244.342.350.1 
Dividends per share (Unadj.) Rs2.002.002.002.502.50 
Adj. dividends per shareRs2.002.002.002.502.50 
Avg Dividend yield %0.20.30.30.60.7 
Book value per share (Unadj.) Rs159.2182.6198.3214.7249.6 
Adj. book value per shareRs159.2182.6198.3214.7249.6 
Shares outstanding (eoy) m282.17282.17282.17282.17282.17 
Bonus / Rights / Conversions  00000 
Price / Sales ratio x2.72.31.71.11.0 
Avg P/E ratio x21.925.418.215.011.2 
P/CF ratio (eoy) x17.718.513.59.87.7 
Price / Book Value ratio x5.44.03.01.91.5 
Dividend payout %5.17.06.19.17.3 
Avg Mkt Cap Rs m242,989204,205168,617116,775108,353 
No. of employees `000NANANANANA 
Total wages/salary Rs m16,40818,71820,56122,54823,437 
Avg. sales/employee Rs Th00000 
Avg. wages/employee Rs Th00000 
Avg. net profit/employee Rs Th00000 
GLENMARK PHARMA INCOME DATA
Net Sales Rs m89,73190,45898,655106,410109,439 
Other income Rs m3749142,0811,596502 
Total revenues Rs m90,10591,372100,736108,006109,941 
Gross profit Rs m19,55816,15417,53017,31021,289 
Depreciation Rs m2,6443,0193,2594,1724,436 
Interest Rs m2,3732,8563,3463,7733,531 
Profit before tax Rs m14,91411,19313,00610,96113,825 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m3,8273,1553,7563,2014,124 
Profit after tax Rs m11,0888,0399,2507,7609,701 
Gross profit margin %21.817.917.816.319.5 
Effective tax rate %25.728.228.929.229.8 
Net profit margin %12.48.99.47.38.9 
GLENMARK PHARMA BALANCE SHEET DATA
Current assets Rs m68,74669,88766,96868,03673,596 
Current liabilities Rs m27,02732,87940,21141,26042,010 
Net working cap to sales %46.540.927.125.228.9 
Current ratio x2.52.11.71.61.8 
Inventory Days Days55567 
Debtors Days Days9894818386 
Net fixed assets Rs m35,78042,86452,09064,25567,093 
Share capital Rs m282282282282282 
"Free" reserves Rs m44,62951,24855,66460,28670,148 
Net worth Rs m44,91151,53055,94660,56870,430 
Long term debt Rs m45,36341,41835,73840,43038,888 
Total assets Rs m104,526112,751119,058132,291140,689 
Interest coverage x7.34.94.93.94.9 
Debt to equity ratio x1.00.80.60.70.6 
Sales to assets ratio x0.90.80.80.80.8 
Return on assets %12.99.710.68.79.4 
Return on equity %24.715.616.512.813.8 
Return on capital %19.115.117.814.615.9 
Exports to sales %00000 
Imports to sales %00000 
Exports (fob) Rs m00000 
Imports (cif) Rs m00000 
Fx inflow Rs m56,15236,31762,99847,73735,753 
Fx outflow Rs m8,0849,72022,85918,88112,023 
Net fx Rs m48,06726,59840,14028,85623,729 
GLENMARK PHARMA CASH FLOW
From Operations Rs m 6,574 16,481 13,242 13,924 11,312 
From Investments Rs m -7,123 -10,133 -6,990 -7,835 -6,752 
From Financial Activity Rs m 5,432 -4,685 -7,387 -4,447 -4,418 
Net Cashflow Rs m 1,992 1,770 -2,971 1,740 278 
* Results Consolidated
Source: Accord Fintech, Equitymaster

Share Holding

Promoters 46.7%
Institution 35.1%
Non-Institution 18.3%
Total 100.0%
Free Float 53.4%
Pledged promoter holdings 0.0%
Shareholding as on Mar 2022
 

Company Information

Regd Off B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai - 400026
E-mail webmaster@glenmarkpharma.com Web www.glenmarkpharma.com
Tel Fax
Sector PHARMACEUTICALS Group Glenmark
Tr Agent K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.), Karvy Selenium Tower B Plot 31-32, Gachibowli Financial District, Nanakramguda
Auditor Walker, Chandiok & Co.
CHM: Glenn Saldanha COMP SEC: Harish Kuber YEAR OF INC: 1977 BSE CODE: 532296 FV (Rs): 1 DIV YIELD (%): 0.6

Read: GLENMARK PHARMA 2020-21 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    

Compare GLENMARK PHARMA With:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    


Yellow Ad

Advertisement

How to Find One Stock with Crorepati Potential?

There are three critical characteristics that differentiate a common stock from a potential 'crorepati' stock.

And we are going to reveal them during our 'One Stock Crorepati' MEGA summit on 30th June.

If you are interested in finding a potential 'crorepati' stock, don't miss this.

At this MEGA Summit we will reveal details of what we call a 'crorepati' stock...

You just cannot afford to miss this summit for anything.

Learn more



Today's Market

Sensex, Nifty Rebound from Day's Low to End Flat; IT & Auto Stocks Witness Buying(Closing)

Indian share markets witnessed a volatile trading session today as crude oil prices rebounded following last week's rout.

Views on news

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks (Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Best Monopoly Stocks to Own in 2022 Views On News (Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

Is it Time to Start Buying Stocks Selectively? (Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

The One Smallcap Stock I'll Recommend Now (Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

When Will the Stock Market Recover? (Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - VINEET LABORATORIES COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS